HWHG(SH:600079) Ge Long Hui A P P·2025-11-21 08:02Core Insights - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Dexmethylphenidate Hydrochloride Capsules from the National Medical Products Administration [1] - This drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 and above [1] - Currently, there are no similar products available in the domestic market or approved for import, indicating a potential market opportunity for the company [1] Financial and R&D Investment - The cumulative R&D investment for this project by Yichang Renfu is approximately 90 million RMB [1] - The acceptance of the drug registration application marks the entry of this product into the review phase, which, if successfully approved, will enhance the company's product line and market competitiveness [1]